Konjenital Kalp cerrahisinde Uzaktan İskemik Önkoşullama İle Miyokardiyal Koruma: Bekleneni Sağlıyor Mu?

Yıl 2023, Cilt: 7 Sayı: 3, 192 - 200, 25.10.2023

Akın Arslan , Emir Cantürk Turgut Aksoy

https://doi.org/10.34084/bshr.1357005

Öz

Amaç: Antioksidan ajanların organ fonksiyonları üzerindeki koruyucu etkilerinin keşfedilmesi, bu sistemin yapay olarak test edilmesine olanak sağlamıştır. Konjenital kalp defekti olan hastalarda uzaktan iskemik önkoşullamanın cerrahi klinik sonuçlar üzerindeki etkisi belirsizdir. Bu çalışma iskemik önkoşullamanın kardiyak koruma üzerindeki erken sonuçlarını araştırdı.
Yöntemler: Tek merkezde kompleks konjenital kalp cerrahisi uygulanan tüm hastaların prospektif incelemesi yapıldı. Rastgele gruplandırılmış hastalardan alınan kan örneklerinde antioksidan enzimatik analiz yapıldı.
Bulgular: Hastaların ortanca cerrahi yaşı iskemik önkoşullama grubunda (grup 1) 19,1 ay (3,7-57,7), kontrol grubunda (grup 2) 16,7 ay (7,8-35,9) idi. Hastaların ortanca takip süresi grup 1'de 58,3 ay (54,3-62,1), grup 2'de 37,1 ay (34,8-41,7) idi. Erken mortalite 4 (%4,4) hastada görüldü. Geç mortalite görülmedi. Süperoksit Dismutaz, Malondialdehit ve kardiyak belirteçlerin düzeyleri açısından gruplar arasında anlamlı fark vardı (p<005).
Sonuç: İskemik önkoşullamanın kardiyak korumaya etkisi henüz kanıtlanmamıştır. Özellikle doğuştan kalp hastalarında hipoksi, siyanoz gibi kronik uyaranlar ya da ameliyat öncesinde kullanılan ilaçlar çalışmanın sonuçlarını etkileyebilmektedir. Bu hastalarda mortalite açısından anlamlı bir fark olmasa da hastanede kalış süresine olumlu etki umut vericidir.

Anahtar Kelimeler

İskemik Önkoşullama, Konjenital Kalp Defekti, Miyokardiyal Koruma

Myocardial Protection With Remote Ischemic Preconditioning In Congenital Heart Surgery: Does It Deliver What Is Expected?

Öz

Objective: The discovery of the protective effects of antioxidant agents on organ functions enabled this system to be tested artificially. The impact of remote ischemic preconditioning (RIPC) on surgical clinical outcomes in patients with congenital heart defects is unclear. This study investigated the early consequences of ischemic preconditioning on cardiac protection.
Methods: The study was designed prospectively. Cuffs were applied to one leg of patients in Group 1 (RIPC) after induction of anesthesia in three cycles (5 min inflation followed by 5 min reperfusion) to precondition ischemia-reperfusion. Antioxidant and cardiac marker levels were recorded in blood samples.
Results: The patients' surgical median age was 19.1 months (IQR= 3.7- 57.7 months) in Group 1 (RIPC) and 16.7 months (IQR= 7.8- 35.9 months) in Group 2 (Control). The patients' median follow-up period was 58.3 months (IQR= 54.3- 62.1 months) in group 1 and 37.1 months (IQR= 34.8- 41.7 months) in group 2. Hospital mortality was in 7 (10.4%) patients. There was no late mortality. There was a significant difference between the groups in terms of Superoxide Dismutase (SOD) and Malondialdehyde (MDA) levels (p<005).
Conclusion: The effects of ischemic preconditioning on cardiac protection have not been proven yet. Especially in congenital cardiac patients, chronic stimuli such as hypoxia and cyanosis or drugs used before surgery may affect the study’s results. Although there is no significant difference in mortality in these patients, a positive effect on the length of hospital stay is promising.

Anahtar Kelimeler

Congenital Heart Defect, Ischemic Preconditioning, Myocardial Protection

Kaynakça

• Referans1 Butts RJ, Scheurer MA, Atz AM, Zyblewski SC, Hulsey TC, Bradley SM, Graham EM. Comparison of the maximum vasoactive inotropic score and low cardiac output syndrome as markers of early postoperative outcomes after neonatal cardiac surgery. Pediatr Cardiol. 2012 Apr;33(4):633-8
• Referans2 Graham EM, Atz AM, Butts RJ, Baker NL, Zyblewski SC, Deardorff RL, et al. Standardized preoperative corticosteroid treatment in neonates undergoing cardiac surgery: results from a randomized trial. J Thorac Cardiovasc Surg. 2011; 142(6):1523–1529.
• Referans3 Hoffman TM, Wernovsky G, Atz AM, Kulik TJ, Nelson DP, Chang AC, et al. Efficacy and safety of milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease. Circulation. 2003; 107(7):996–1002.
• Referans4 Kulik TJ, Moler FW, Palmisano JM, Custer JR, Mosca RS, Bove EL, et al. Outcome-associated factors in pediatric patients treated with extracorporeal membrane oxygenator after cardiac surgery. Circulation. 1996; 94(9 Suppl): II63–II68.
• Referans5 Mosca MS, Narotsky DL, Mochari-Greenberger H, Liao M, Mongero L, Beck J, Bacchetta M. Duration of conventional cardiopulmonary resuscitation before extracorporeal cardiopulmonary resuscitation and survival among adult cardiac arrest patients. Perfusion. 2016 Apr;31(3):200-6.
• Referans6 Meert KL, Delius R, Slomine BS, Christensen JR, Page K, Holubkov R, Dean JM, Moler FW; Therapeutic Hypothermia after Pediatric Cardiac Arrest Trial Investigators. One-Year Survival and Neurologic Outcomes After Pediatric Open-Chest Cardiopulmonary Resuscitation. Ann Thorac Surg. 2019 May;107(5):1441-1446.
• Referans7 Sies H. Biochemistry of oxidative stress. Angewandte Chemie 25: 1058–1071, 1986
• Referans8 Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74:1124-36
• Referans9 Lieberthal W, Wolf EF, Rennke HG, Valeri CR, Levinsky NG. Renal ischemia and reperfusion impair endothelium-dependent vascular relaxation. Am J Physiol. 1989 May;256(5 Pt 2): F894-900.
• Referans10 Pantke U, Volk T, Schmutzler M, Kox WJ, Sitte N, and Grune T. Oxidized proteins as a marker of oxidative stress during coronary heart surgery. Free Radic Biol Med 27: 1080–1086, 1999
• Referans11 WHO. Biomarkers in Risk assessment: Validity and Validation. Geneva: WHO, 2001
• Referans12 Fattman CL. Schaefer LM. Oury TD. Extracellular superoxide dismutase in biology and medicine. Free Radic Biol Med. 2003; 35:236–256.
• Referans13 Fukai T. Folz RJ. Landmesser U. Harrison DG. Extracellular superoxide dismutase and cardiovascular disease. Cardiovasc Res. 2002; 55:239–249.
• Referans14 Qin Z. Reszka KJ. Fukai T. Weintraub NL. Extracellular superoxide dismutase (ecSOD) in vascular biology: an update on exogenous gene transfer and endogenous regulators of ecSOD. Transl Res. 2008; 151:68–78.
• Referans15 Gaies, M. G., Gurney, J. G., Yen, A. H., Napoli, M. L., Gajarski, R. J., Ohye, R. G., … Hirsch, J. C. (2010). Vasoactive–inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass*. Pediatric Critical Care Medicine, 11(2), 234–238.
• Referans16 Jacobs, J. P., Jacobs, M. L., Maruszewski, B., Lacour-Gayet, F. G., Tchervenkov, C. I., Tobota, Z., … Mavroudis, C. (2012). Initial application in the EACTS and STS Congenital Heart Surgery Databases of an empirically derived methodology of complexity adjustment to evaluate surgical case mix and results. European Journal of Cardio-Thoracic Surgery, 42(5), 775–780.
• Referans17 Esterbauer H, Schaur RJ, and Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11: 81–128, 1991
• Referans18 Frijhoff J, Winyard PG, Zarkovic N, Davies SS, Stocker R, Cheng D, Knight AR, Taylor EL, Oettrich J, Ruskovska T, Gasparovic AC, Cuadrado A, Weber D, Poulsen HE, Grune T, Schmidt HH, Ghezzi P. Clinical Relevance of Biomarkers of Oxidative Stress. Antioxid Redox Signal. 2015 Nov 10;23(14):1144-70.
• Referans19 Miao, L., & St Clair, D. K. (2009). Regulation of superoxide dismutase genes: implications in disease. Free radical biology & medicine, 47(4), 344–356.
• Referans20 Elroy-Stein O. Bernstein Y. Groner Y. Overproduction of human Cu/Zn-superoxide dismutase in transfected cells: extenuation of paraquat-mediated cytotoxicity and enhancement of lipid peroxidation. EMBO J. 1986; 5:615–622.
• Referans21 Epstein CJ. Avraham KB. Lovett M. Smith S. Elroy-Stein O. Rotman G. Bry C. Groner Y. Transgenic mice with increased Cu/Zn-superoxide dismutase activity: animal model of dosage effects in Down syndrome. Proc Natl Acad Sci USA. 1987; 84:8044–8048.
• Referans22 Mezzetti A, Di Ilio C, Calafiore AM, Aceto A, Marzio L, Frederici G, Cuccurullo F. Glutathione peroxidase, glutathione reductase, and glutathione transferase activities in the human artery, vein, and heart. J Mol Cell Cardiol. 1990 Sep;22(9):935-8.
• Referans23 Spiteller G. Linoleic acid peroxidation—the dominant lipid peroxidation process in low density lipoprotein—and its relationship to chronic diseases. Chem Phys Lipids 95: 105–162, 1998